Compass Pathways reported positive Phase 3 results, effects lasting 6 months, and $433 million in cash for operations through launch and into 2028. Its planned Q4 2026 drug filing and possible faster approval still depend on review, but the trial results and cash support its outlook.
The results make COMP360's path toward U.S. review more credible, and the cash gives Compass time to prepare for a launch. The company still needs FDA review, and faster approval is only a possibility.
Follow Compass Pathways (CMPS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CMPS